BST Position Update – January 8, 2016

| January 8, 2016

BST Position Update

. . . . CoLucid Pharmaceuticals (NASDAQ: $CLCD) – Hold 

CLCD reached a high of $8.95 this week.  That pushed the gains on this biotech stock to 90% from our buy price.

The company is working on a new treatment for migraine headaches.  They are working on the first of two Phase 3 clinical trials.

Needless to say, this could be a blockbuster.  Continue holding for more upside. 

. . . . OncoMed Pharmaceuticals (NASDAQ: $OMED) – Hold 

OMED recently announced that they received $70 million for reaching a milestone on the development of demcizumab.  The company ended the year with $227 million in cash.  That’s enough to keep the company running for the next year and beyond.

The stock is up 57% from the 52-week low and we are up 38% from our buy price.  It is currently battling a stiff layer of resistance around $23.00.  We could see some volatility in the stock price before it breaks out.

Continue holding.

Action To Take

  • Hold CLCD
  • Hold OMED

Category: BST Update

About the Author ()

Comments are closed.

«
»